Brief: Atea Pharmaceuticals Highlights Strategic Priorities For 2023
09/01/2023 13:09
Jan 9 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS HIGHLIGHTS STRATEGIC PRIORITIES FOR
2023
* ATEA PHARMACEUTICALS INC - PROOF-OF-CONCEPT RESULTS FOR
AT-752
FOR DENGUE EXPECTED 1Q23
Source text for Eikon: ID:nGNX3C8Rrb
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM